ArticleJournal of materials science. Materials in medicine2025
In vitro experimental study of MC-PMMA containing vancomycin for the prevention of infection in open bone defects.
Article in Journal of materials science. Materials in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
In this study, vancomycin, bone cement (PMMA) and mineralized collagen (MC) were mixed in order to obtain a new composite drug-carrying biomaterial, which has good results in both drug slow release, good biocompatibility, and good growth of osteoblasts, osteoclasts, and mesenchymal stem cells on the surface of the biomaterial, which provides a new therapeutic idea for the clinical treatment of bone defect infections. In this study, the drug retardation system of vancomycin and mineralized collagen composite bone cement-carrying biomaterials was prepared in proportion to the drug retardation system, and the experimental studies were carried out using electron microscope scanning, HPLC drug retardation analysis, in vitro antimicrobials, and co-cultivation of osteoclasts, osteoblasts, and mesenchymal stem cells. We found that the composite drug-carrying material of vancomycin, bone cement and mineralized collagen had good slow-release effect and antimicrobial properties, and the addition of vancomycin and bone cement to mineralized collagen material had even better drug-release efficiency than that of bone cement plus vancomycin alone. In vitro antimicrobial showed that the composite material has excellent antimicrobial effect against Staphylococcus aureus. Co-culture of osteoblasts, osteoclasts and mesenchymal stem cells with the material showed that the cells were morphologically complete on the surface of the composites with good growth status. Vancomycin, bone cement and mineralized collagen composite drug-carrying biomaterials have excellent slow-release effect and antimicrobial properties with good biocompatibility, which is a new therapeutic idea for the future clinical treatment of bone defect infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.